Cargando…

Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine

Prior studies suggest that adverse events (AEs) following doses one and two of BNT162b2/Pfizer vaccine are worse in those with a prior history of COVID-19. To establish whether this outcome applies to a third/booster dose, we conducted a survey with 534 healthcare workers (HCW) in Northeast England,...

Descripción completa

Detalles Bibliográficos
Autores principales: Raw, Rachael K., Rees, Jon, Chadwick, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10021629/
https://www.ncbi.nlm.nih.gov/pubmed/36963011
http://dx.doi.org/10.1371/journal.pgph.0001053
_version_ 1784908539619180544
author Raw, Rachael K.
Rees, Jon
Chadwick, David R.
author_facet Raw, Rachael K.
Rees, Jon
Chadwick, David R.
author_sort Raw, Rachael K.
collection PubMed
description Prior studies suggest that adverse events (AEs) following doses one and two of BNT162b2/Pfizer vaccine are worse in those with a prior history of COVID-19. To establish whether this outcome applies to a third/booster dose, we conducted a survey with 534 healthcare workers (HCW) in Northeast England, who reported AEs following all three doses of BNT162b2/Pfizer vaccine. We also explored AEs associated with concurrent seasonal influenza immunisation, in a subset of 492 HCWs. For all doses of BNT162b2/Pfizer vaccine there was a cluster of systemic AEs that were consistently worse in HCWs with a prior history of COVID-19. AEs were no worse in HCWs who received their third/booster dose within 7 days of the influenza jab, rather than further apart. Gender and the presence of ongoing COVID-19 symptoms (OCS) had no effect on AEs associated with COVID-19 or influenza vaccination, though younger HCWs experienced more AEs overall. Our findings have implications for vaccine hesitancy and immunisation protocols.
format Online
Article
Text
id pubmed-10021629
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-100216292023-03-17 Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine Raw, Rachael K. Rees, Jon Chadwick, David R. PLOS Glob Public Health Research Article Prior studies suggest that adverse events (AEs) following doses one and two of BNT162b2/Pfizer vaccine are worse in those with a prior history of COVID-19. To establish whether this outcome applies to a third/booster dose, we conducted a survey with 534 healthcare workers (HCW) in Northeast England, who reported AEs following all three doses of BNT162b2/Pfizer vaccine. We also explored AEs associated with concurrent seasonal influenza immunisation, in a subset of 492 HCWs. For all doses of BNT162b2/Pfizer vaccine there was a cluster of systemic AEs that were consistently worse in HCWs with a prior history of COVID-19. AEs were no worse in HCWs who received their third/booster dose within 7 days of the influenza jab, rather than further apart. Gender and the presence of ongoing COVID-19 symptoms (OCS) had no effect on AEs associated with COVID-19 or influenza vaccination, though younger HCWs experienced more AEs overall. Our findings have implications for vaccine hesitancy and immunisation protocols. Public Library of Science 2023-02-17 /pmc/articles/PMC10021629/ /pubmed/36963011 http://dx.doi.org/10.1371/journal.pgph.0001053 Text en © 2023 Raw et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Raw, Rachael K.
Rees, Jon
Chadwick, David R.
Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine
title Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine
title_full Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine
title_fullStr Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine
title_full_unstemmed Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine
title_short Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine
title_sort increased adverse events following third dose of bnt162b2/pfizer vaccine in those with previous covid-19, but not with concurrent influenza vaccine
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10021629/
https://www.ncbi.nlm.nih.gov/pubmed/36963011
http://dx.doi.org/10.1371/journal.pgph.0001053
work_keys_str_mv AT rawrachaelk increasedadverseeventsfollowingthirddoseofbnt162b2pfizervaccineinthosewithpreviouscovid19butnotwithconcurrentinfluenzavaccine
AT reesjon increasedadverseeventsfollowingthirddoseofbnt162b2pfizervaccineinthosewithpreviouscovid19butnotwithconcurrentinfluenzavaccine
AT chadwickdavidr increasedadverseeventsfollowingthirddoseofbnt162b2pfizervaccineinthosewithpreviouscovid19butnotwithconcurrentinfluenzavaccine